Condition: Recurrent Implantation Faliure · Sponsor: Fakih IVF Fertility Center
Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.
This description comes directly from the study's public registry record.
Dr. Lamiya Mohiyiddeen, MD, FRCOG · +971543676002 · lamiya.mohiyiddeen@fakihivf.com
Fatma Bathawab, PhD · +971585707393 · fatma.bathawab@fakihivf.com
Always discuss trial participation with your own doctor first.
| Fakih IVF | Abu Dhabi, United Arab Emirates | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07675980